Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostics company, utilizes microRNAs, a collection of recently discovered non-coding control genes, to develop a broad array of tests for cancers and women’s health indications. These non-coding genes have demonstrated to be highly sensitive and tissue specific biomarkers. The company’s early recognition of microRNAs’ vast potential has led to great discovery and has the establishment of a leading intellectual property (IP) portfolio. For further information, visit the Company’s web site at www.rosettagenomics.com.
- 17 years ago
QualityStocks
Rosetta Genomics, Ltd. (NASDAQ: ROSG)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Identifies Multiple Structurally Controlled REE Targets at Atikokan Property
This article has been disseminated on behalf of Powermax Minerals Inc. and may include paid advertising. Powermax Minerals (CSE: PMAX) (OTCQB:…
-
QualityStocksNewsBreaks – Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) Advances Rare Earth Assets with Clear Path to Development
Disseminated on behalf of Search Minerals Inc. (TSX.V: SMY) (OTC: SHCMF) and may include paid advertising. Search…
-
Safe & Green Holdings Corp. (NASDAQ: SGBX) Comprehensive Rebranding Plan Reflects Transformation into Fully Integrated Energy Infrastructure Platform, with Acquisition Growth Model
Safe & Green Holdings Corp. plans to rebrand as Olenox Industries Inc., aligning its identity…